HUM vs ZBH
Humana vs Zimmer Biomet — AI-powered side-by-side comparison
| Metric | HUM | ZBH |
|---|
| AI Score |
52
|
66
|
| Price |
$386.32
|
$100.86
|
| P/E Ratio |
35.57×
|
24.45×
|
| ROE |
6.7%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
13.7%
|
69.9%
|
| Debt / Equity |
0.74×
|
0.59×
|
| Dividend Yield |
0.9%
|
1.0%
|
| RSI (14) |
47.3
|
63.4
|
| Beta |
0.74
|
0.462
|
| Expected Upside |
+12.9%
|
+0.4%
|
AI Committee View
Current Innellis committee reasoning for HUM versus ZBH.
ZBH leads by 14 points.
ZBH scores 66/100 (Buy) versus HUM at 52/100 (Watch).
HUM Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case. Risk Analyst remains cautious — current ratio of 0.01 is tight -- limited short-term liquidity cushion. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- News sentiment is positive (+0.20 across 30 articles, 14d) — News
Bear Case
- P/E of 36.1 is moderate-to-rich — Value
- EPS declining -19.0% YoY despite any revenue growth — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
ZBH Committee View
80% agreement
5 analysts
The primary driver is price-to-book of 1.4x is a discount to asset value. The main limiting factor is daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical